Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases in the United States. The company markets Recorlev for the treatment of endogenous hypercortisolemia in Cushing’s syndrome, Gvoke for severe hypoglycemia in patients with diabetes, and Keveyis for Primary Periodic Paralysis. Its pipeline includes XP-8121, a once-weekly subcutaneous injection of levothyroxine for hypothyroidism, which utilizes the company’s proprietary non-aqueous formulation technologies XeriSol and XeriJect. Xeris also pursues formulation and development partnerships to apply these technologies to other companies’ drugs and biologics. The company acquired Keveyis through the acquisition of Strongbridge Biopharma plc.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage xerispharma.com
Sector Healthcare IR page xerispharma.com/investor-relations
Tags
endocrine diseases, neurological diseases, cushing's syndrome, severe hypoglycemia, primary periodic paralysis, hypothyroidism, non-aqueous formulations, glucagon, cortisol synthesis inhibitors, dichlorphenamide, Recorlev, Gvoke, Gvoke PFS, Gvoke HypoPen, Gvoke Kit, Keveyis, XP-8121, XeriSol, XeriJect, Strongbridge Biopharma plc
Press page —

Metrics

Valuation  
Market cap $ 2.28B
Market cap (USD) $ 2.28B
P/E -312.22
PEG —
P/BV 46.74
P/S 6.19
P/OCF 30.96
P/FCF 81.63
Dividend yield —
Turnover / mcap —
Returns  
ROE 4.0%
ROI 0.24%
ROIC 8.0%
Profit margin 0.19%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 388.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score 11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 291.845M 203.07M 163.914M 110.248M 49.28M 20.155M 1.627M 100K 16K
Net profit 554K -54.836M -62.255M -94.66M -122.725M -91.14M -125.58M -60.08M -26.554M
Free cash flow 27.93M -37.849M -49.286M -103.415M -96.62M -80.935M -105.453M -57.789M -25.363M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 7.85 3.39 2.35 1.33 2.93 4.06 8.55 15.82 —
Price performance 12m 1.32 0.44 0.77 -0.55 -0.28 -0.53 -0.46 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 1.2M 2.87M 4.69M 6.88M 17.5M 30.8M 39.2M 40.4M 51.1M
↳ YoY growth +139.3% +63.6% +46.5% +153.9% +76.6% +27.1% +3.1% +26.3%
↳ 5y CAGR +91.4% +68.7% +53.8% +49.3%
Borrowings, current (USD) — — 0.00 — — — — 0.00 15.1M 0.00
Borrowings, non-current (USD) — — 35M — — — — 191M 217M 220M
Lease liabilities (USD) — — — — — 0.00 11M 38.3M 39.3M 37.8M
Cash and deposits (USD) 32.3M 42M 45.7M 19.5M 37.6M 67.3M 122M 67.4M 71.6M 111M
Intangible assets (USD) — — — — 0.00 131M 121M 110M 98.9M 88.1M
Right-of-use assets (USD) — — — — — 0.00 3.99M 23.2M 22.6M 22.1M
Net debt (borrowings + leases - cash) (USD) — — -10.7M — — — — -29.2M 200M 147M
Cash flow detail
Operating cash flow (USD) — -24.7M -56.3M -104M -80.6M -95.5M -103M -47M -37M 28.6M
Purchases of property, plant and equipment (USD) — 700,000 1.51M 1.11M 377,000 -1.09M — — — —
Change in receivables (cash effect) (USD) — 1.1M 1.67M 4.69M 2.18M -6.24M -13.4M -8.37M -1.22M -10.6M
Change in inventories (cash effect) (USD) — — 0.00 2.18M 5.14M -7.42M -7.47M -14.8M -8.78M -19.3M
Change in payables (cash effect) (USD) — 661,000 -1.11M 4.74M -2.49M 5.53M -4.32M 6.96M -9.61M -69,000
Interest paid (cash effect) (USD) — -2,000 -1.71M -3.72M -4.56M -7.29M -10.9M -27.7M -26.9M -27.1M
Share-based compensation (USD) — 499,000 1.73M 6.48M 8.27M 11.4M 12.2M 10.7M 18.4M 22.4M
Operating cash flow before change in receivables (USD) — -25.8M -57.9M -109M -82.7M -89.3M -89.5M -38.7M -35.8M 39.3M
Free cash flow (OCF - PPE - intangibles) (USD) — -25.4M -57.8M -105M -80.9M -96.6M — — — —
Income detail
Research and development expense (USD) — 20.2M 40.7M 60.4M 20.9M 25.2M 21M 22.3M 25.6M 31.2M
↳ 5y CAGR +0.8% -11.3% -15.8% +8.3%
Total comprehensive income (USD) — — -52,000 95,000 -37,000 -123M -94.7M -62.3M -54.8M 554,000
Comprehensive income to owners (USD) — — -52,000 95,000 -37,000 -123M -94.7M -62.3M -54.8M 554,000
Reported Aug 14, 2018 Mar 6, 2019 Mar 12, 2020 Mar 12, 2020 Mar 11, 2022 Mar 8, 2023 Mar 8, 2023 Mar 6, 2025 Mar 6, 2025 Mar 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

PDF Version

Total revenue increased 44% year-over-year to $107 million

Recorlev net revenue increased 93% year-over-year to more than $71 million

Raises full-year 2026 total revenue guidance to $395 million to $405 million

Raises 2030 total revenue outlook to more than $1 billion, up from approximately $750 million

Conference call and webcast today at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)--Nov. 5, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced its financial results and business highlights for the third quarter ended September 30, 2026.

“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030," said John Shannon, Chairman and Chief Executive Officer of Xeris. "This new trajectory reflects growth from the full enterprise. Net product revenue in the third quarter grew more than 43% year-over-year, led by Recorlev, where our expanded commercial team moved from build to yield and delivered record referrals and new patient starts. We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”

Shannon continued, “We also continued to advance XP-8121 following our comprehensive program overview in September. We remain on track to initiate Cornerstone, our pivotal Phase 3 study, by year-end. Given the strong momentum across Recorlev, Gvoke, and Keveyis, we are raising our full-year total revenue guidance to $395–$405 million.”

Third Quarter 2026 Highlights

| | Three months ended September 30, | | Change |

| | | 2026 | | | 2025 | | $ | % |

| Product revenue (in thousands): | | | | | | |

| Recorlev | $ | 71,540 | | $ | 36,975 | | $ | 34,565 | | 93 | |

| Gvoke | | 21,706 | | | 25,151 | | | (3,445 | ) | (14 | ) |

| Keveyis | | 13,021 | | | 11,937 | | | 1,084 | | 9 | |

| Product revenue, net | | 106,267 | | | 74,063 | | | 32,204 | | 43 | |

| Royalty, contract and other revenue | | 958 | | | 317 | | | 641 | | 202 | |

| Total revenue | $ | 107,225 | | $ | 74,380 | | $ | 32,845 | | 44 | |

Total revenuefor the third quarter of 2026 was $107.2 million, an increase of 44% compared to the same period last year. The increase was primarily driven by increased patient demand for Recorlev. Gvoke delivered stronger-than-historical back-to-school prescription demand in the third quarter, which was offset by a one-time ($4 million) gross-to-net adjustment.

Gross marginimproved to 88% in the third quarter of 2026, up from 85% in the same period last year. The improvement was primarily driven by a favorable product mix.

Research and development (R&D) expenses increased by $3.6 million, or 48%, in the third quarter of 2026 compared to the same period last year. The increase in R&D expenses primarily reflects spend to support XP-8121.

Selling, general and administrative (SG&A) expensesincreased by $17.6 million, or 38%, in the third quarter of 2026 compared to the same period last year. This increase mainly reflects higher personnel-related expenses to support the commercial enterprise, including the Recorlev expansion.

Net income for the third quarter of 2026 was $11.3 million, compared to net income of $0.6 million in the same period last year.

Adjusted EBITDA1for the third quarter of 2026 was $30.8 million, an improvement of $13.3 million compared to the same period last year.

Year-to-Date Highlights (As of September 30, 2026)

| | Nine months ended September 30, | | Change |

| | | 2026 | | | 2025 | | $ | % |

| Product revenue (in thousands): | | | | | | |

| Recorlev | $ | 178,088 | | $ | 93,949 | | $ | 84,139 | | 90 | |

| Gvoke | | 65,055 | | | 69,463 | | | (4,408 | ) | (6 | ) |

| Keveyis | | 36,582 | | | 34,849 | | | 1,733 | | 5 | |

| Other product revenue | | — | | | 1,312 | | | (1,312 | ) | — | |

| Product revenue, net | | 279,725 | | | 199,573 | | | 80,152 | | 40 | |

| Royalty, contract and other revenue | | 2,727 | | | 6,465 | | | (3,739 | ) | (58 | ) |

| Total revenue | $ | 282,452 | | $ | 206,038 | | $ | 76,413 | | 37 | |

Total revenuewas $282.5 million for the nine months ended September 30, 2026, an increase of 37% compared to the same period last year. The increase was primarily driven by increased patient demand for Recorlev.

Gross marginimproved to 87%, up from 84% in the same period last year. The improvement was primarily driven by favorable product mix.

Research and development (R&D) expenses increased $7.2 million or 31% for the nine months ended September 30, 2026, compared to the same period last year. The increase in R&D expenses primarily reflects spend to support XP-8121.

Selling, general and administrative (SG&A) expensesincreased $43.4 million or 32% for the nine months ended September 30, 2026, compared to the same period last year. This increase mainly reflects higher personnel-related expense to support the commercial enterprise, including the Recorlev expansion.

Net loss for the nine months ended September 30, 2026, was $17.6 million, compared to a net loss of $10.5 million in the same period last year. The loss was due to a one-time, non-cash charge of approximately $30.8 million in the second quarter of 2026, reflecting the increase in fair value as a result of entering into the 2028 Convertible Notes exchange agreements.

Adjusted EBITDA1for the nine months ended September 30, 2026, was $65.1 million, an improvement of $30.8 million compared to the same period last year.

Total Shares Outstanding were 182,700,038 at October 30, 2026.

Key Business Highlights

  • 2028 Convertible Notes Fully Retired: On July 15, 2026, Xeris completed the retirement of all of its 8.00% Convertible Senior Notes due 2028 through a combination of cash and the issuance of shares of common stock, eliminating approximately $34 million of debt and approximately $3 million in annual interest expense. No 2028 Convertible Notes remain outstanding, and there were no charges related to the notes in the third quarter of 2026.

  • XP-8121 Program Overview: On September 9, 2026, Xeris hosted a program overview detailing the comprehensive clinical development program for XP-8121, its investigational once-weekly subcutaneous levothyroxine for hypothyroidism. The pivotal Phase 3 Cornerstone study is designed to demonstrate that XP-8121 is therapeutically equivalent to daily oral levothyroxine and is expected to enroll 500 adults and adolescents with well-controlled hypothyroidism at more than 50 U.S. sites, randomized 1:1 for 54 weeks. The program also includes Capstone, a pediatric study; Touchstone, a study in patients with inconsistent thyroid control despite oral therapy; and a real-world evidence program. Xeris remains on track to initiate Cornerstone by year-end 2026, with topline data expected in late 2028 and potential approval and launch in 2030. A replay and accompanying materials are available under the “Events” section of the Xeris Investor Relations website.

  • Third U.S. Patent Granted for XP-8121: On October 6, 2026, the United States Patent and Trademark Office (USPTO) granted Xeris U.S. Patent No. 12,751,937, entitled “Stable Levothyroxine Compositions In Aprotic Polar Solvents,” which is expected to expire on October 19, 2043. This is the third U.S. patent issued for XP-8121, the Company’s investigational drug product candidate for hypothyroidism.

  • New Patent Issued Covering Keveyis: On October 13, 2026, the USPTO issued U.S. Patent No. 12,758,502 from U.S. Patent Application No. 17/151,405, entitled “Compositions and Methods of Use.” The claims cover the use of the Company’s KEVEYIS® (dichlorphenamide) product, and the patent is expected to provide intellectual property protection for Keveyis through at least 2043.

  • Scientific Presentations: Xeris presented real-world data at the 2026 Breakthrough T1D Clinical & Research Congress on October 9, examining healthcare provider awareness of American Diabetes Association guidelines for prescribing ready-to-use glucagon versus actual prescribing practices. The presentation, titled “Ensuring Readiness: A Case For Proactive Glucagon Prescribing For Patients At Increased Risk of Severe Hypoglycemia,” highlighted the unmet clinical need and opportunity to increase adoption of ready-to-use glucagon products. At the 21st Annual Cardiometabolic Health Congress on October 15–16, Xeris presented a case study titled “Discontinuation of Antihypertensives and Insulin in a Patient with Difficult-to-Control Type 2 Diabetes and Hypertension After Treatment With Levoketoconazole,” demonstrating cortisol normalization accompanied by improvements in multiple cardiometabolic parameters.

  • Menassie M. Taddese appointed to the Xeris Biopharma Board of Directors: Mr. Taddese joined the Xeris Board of Directors as an independent director, effective November 2, 2026. Mr. Taddese is an accomplished biopharmaceutical executive with nearly 30 years of global biopharmaceutical leadership experience, with a track record spanning commercial operations, corporate finance, business transformation and corporate governance.

Upcoming Events

  • American Thyroid Association 95th Annual Meeting: Xeris will present, for the first time publicly, a TriNetX real-world evidence analysis at the ATA Annual Meeting, being held November 4–7, 2026, in Philadelphia, PA. The retrospective analysis evaluates the feasibility of identifying and longitudinally assessing a large population of patients treated with oral levothyroxine using linked treatment records and TSH laboratory data, establishing a foundation for future real-world evidence research. At the meeting, Xeris will also unveil details of its investigator-initiated research grant program for hypothyroidism.

  • Jefferies London Healthcare Conference: Senior management will participate in 1x1 meetings and a fireside chat from November 16-19, 2026, in London. The fireside chat on Tuesday, November 17, will be webcast live with access available via the "Events" section of Xeris' Investor Relations website. Please contact the sponsor to arrange meetings with management.

  • Piper Sandler Healthcare Conference: Senior management will participate in 1x1 meetings and a fireside chat on December 1, 2026, in New York. The fireside chat on Tuesday, December 1, will be webcast live with access available via the "Events" section of Xeris' Investor Relations website. Please contact the sponsor to arrange meetings with management.

Conference Call and Webcast Details

Xeris will host a conference call and webcast at 8:30 a.m. Eastern Time today to discuss the Company's financial and operational results. Interested parties may pre-register for the call by following https://events.q4inc.com/attendee/168342968. Attendees can also join via the “Events” section of the Xeris Investor Relations website.

The webcast, replay, and other information related to the event can be accessed on the investor website https://xerispharma.com/investor-relations.

| 1 Adjusted EBITDA is a non-GAAP financial measure. See "Note Regarding Use of Non-GAAP Financial Measures" and the corresponding financial tables at the end of this press release for definitions and reconciliations of non-GAAP measures. |

Note Regarding Use of Non-GAAP Financial Measures

This press release includes financial results prepared in accordance with generally accepted accounting principles in the United States (GAAP) and also certain historical non-GAAP financial measures, namely Adjusted EBITDA. This non-GAAP financial measure is not meant to be considered in isolation and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP, and was not prepared under any comprehensive set of accounting rules or principles. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP, and the calculation of the non-GAAP financial measure included herein may differ from similarly titled measures used by other companies. The Company believes that the presentation of Adjusted EBITDA, when viewed in conjunction with actual GAAP results, provides investors with a more meaningful understanding of the Company's ongoing and projected operating performance, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. The Company believes this non-GAAP financial measure helps indicate underlying trends in the Company’s business and is important in comparing current results with prior period results and understanding expected operating performance. Also, management uses this non-GAAP financial measure to establish budgets and operational goals, and to manage the Company’s business and evaluate its performance. In addition, management believes that Adjusted EBITDA is important in evaluating the administrative costs of operating the Company’s business.

Adjusted EBITDA is GAAP net income (loss) before income tax (benefit) expense, less interest and other income, plus depreciation and amortization, interest expense, share-based compensation and debt refinancing fees or extinguishment losses.

About Xeris

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines for serious diseases with significant unmet medical need. Xeris has three commercially available products: Recorlev®, a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for the treatment of hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for Xeris and its partners.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

Forward-Looking Statements

Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for Xeris Biopharma Holdings, Inc., including statements regarding the Company’s expected benefits from its commercial investments in Recorlev in the second half of 2026 and beyond; financial guidance for full-year 2026 and the Company’s 2030 outlook for total revenue and Recorlev net revenue, including the potential for revenue growth, the Company’s ability to generate net income, Recorlev’s growth potential, the ability to continue to deliver on all full-year financial targets, the term of intellectual property protection for Keveyis, including the expectation that the recently issued patent will provide intellectual property protection for Keveyis through at least 2043, and the expected term of the Company’s issued patents covering XP-8121; the Company’s intention to protect and strengthen the long-term value of its assets; the effectiveness of the Company’s strategic execution, the Company’s ability to continue on its current growth trajectory and continue to drive patient demand, advancing its strategic initiatives, its ability to create sustainable long-term value for shareholders, the ability to continue to demonstrate sustained momentum across the portfolio and the market and therapeutic and commercial potential of its products and product candidates, including its expectations regarding the timely execution of XP-8121's ongoing development leading into the start of its Phase 3 clinical trial and the expected timing of initiation of the XP-8121 Phase 3 Cornerstone clinical trial by year-end 2026, the expected timing of topline data and potential regulatory approval and launch of XP-8121, and the Company’s comprehensive clinical development plan and commercial opportunity for XP-8121, the potential utility of its formulation platforms, the advancement of its pipeline, and other statements containing the words "achieve," "anticipate," “will,” “would,” “continue,” “expect,” “should,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results (including revenue and sales in the near- and long-term), performance or achievements, industry results, market opportunity and developments to differ materially from those expressed in or implied by such forward-looking statements (including its 2026 guidance and 2030 outlook), include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, its and collaborators’ ability to protect its intellectual property and proprietary technology, the accuracy and completeness of its assumptions and its ability to accurately estimate future financial results and market opportunities, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, political unrest, trade disputes, changes in U.S. governmental priorities and resources, announced or implemented tariffs or export controls and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. The risks described herein and in Xeris’ U.S. Securities and Exchange Commission filings are not the only risks the Company faces. Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.

| XERIS BIOPHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data, unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Product revenue, net | $ | 106,267 | | | $ | 74,063 | | | $ | 279,725 | | | $ | 199,573 | |

| Royalty, contract and other revenue | | 958 | | | | 317 | | | | 2,727 | | | | 6,465 | |

| Total revenue | | 107,225 | | | | 74,380 | | | | 282,452 | | | | 206,038 | |

| Costs and expenses: | | | | | | | |

| Cost of goods sold | | 12,429 | | | | 10,996 | | | | 35,515 | | | | 31,622 | |

| Research and development | | 11,058 | | | | 7,483 | | | | 30,510 | | | | 23,291 | |

| Selling, general and administrative | | 64,108 | | | | 46,459 | | | | 178,287 | | | | 134,870 | |

| Amortization of intangible assets | | 2,711 | | | | 2,711 | | | | 8,132 | | | | 8,132 | |

| Total costs and expenses | | 90,306 | | | | 67,649 | | | | 252,444 | | | | 197,915 | |

| Income from operations | | 16,919 | | | | 6,731 | | | | 30,008 | | | | 8,123 | |

| Other expenses | | (5,629 | ) | | | (6,110 | ) | | | (47,585 | ) | | | (18,650 | ) |

| Net income (loss) before benefit from income taxes | | 11,290 | | | | 621 | | | | (17,577 | ) | | | (10,527 | ) |

| Income tax benefit (expense) | | — | | | | — | | | | — | | | | — | |

| Net income (loss) | $ | 11,290 | | | $ | 621 | | | $ | (17,577 | ) | | $ | (10,527 | ) |

| | | | | | | | |

| Other comprehensive income (loss), net of tax: | | | | | | | |

| Foreign currency translation adjustments | | (1 | ) | | | (1 | ) | | | 14 | | | | — | |

| Comprehensive income (loss) | $ | 11,289 | | | $ | 620 | | | $ | (17,563 | ) | | $ | (10,527 | ) |

| | | | | | | | |

| Net income (loss) per common share - basic | $ | 0.06 | | | $ | 0.00 | | | $ | (0.10 | ) | | $ | (0.07 | ) |

| Net income (loss) per common share - diluted | $ | 0.06 | | | $ | 0.00 | | | $ | (0.10 | ) | | $ | (0.07 | ) |

| | | | | | | | |

| Weighted average common shares outstanding: | | | | | | | |

| Basic | | 180,941,748 | | | | 163,649,932 | | | | 174,800,967 | | | | 158,559,467 | |

| Diluted | | 189,924,032 | | | | 177,617,307 | | | | 174,800,967 | | | | 158,559,467 | |

| XERIS BIOPHARMA HOLDINGS, INC. Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA (in thousands, unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| GAAP Net income (loss) | $ | 11,290 | | | $ | 621 | | | $ | (17,577 | ) | | $ | (10,527 | ) |

| Adjustments | | | | | | | |

| Interest and other income | | (827 | ) | | | (1,158 | ) | | | (3,484 | ) | | | (3,281 | ) |

| Interest expense | | 6,456 | | | | 7,268 | | | | 20,287 | | | | 21,931 | |

| Depreciation and amortization | | 3,029 | | | | 3,049 | | | | 9,110 | | | | 9,110 | |

| EBITDA | $ | 19,948 | | | $ | 9,780 | | | $ | 8,336 | | | $ | 17,233 | |

| Adjustments | | | | | | | |

| Share-based compensation (a) | | 10,802 | | | | 7,643 | | | | 26,008 | | | | 17,094 | |

| Loss on debt extinguishment, net | | — | | | | — | | | | 30,782 | | | | — | |

| Adjusted EBITDA | $ | 30,750 | | | $ | 17,423 | | | $ | 65,126 | | | $ | 34,327 | |

| |

| (a) Includes non-cash, stock-based compensation, net of forfeitures. |

| XERIS BIOPHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |

| |

| | September 30, 2026 | | December 31, 2025 |

| Assets | (unaudited) | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 131,082 | | $ | 111,042 |

| Trade accounts receivable, net | | 68,596 | | | 51,050 |

| Inventory, net | | 76,925 | | | 68,673 |

| Prepaid expenses and other current assets | | 12,662 | | | 9,548 |

| Total current assets | | 289,265 | | | 240,313 |

| Property and equipment, net | | 4,638 | | | 4,945 |

| Operating lease right-of-use assets | | 21,584 | | | 22,112 |

| Goodwill | | 22,859 | | | 22,859 |

| Intangible assets, net | | 79,946 | | | 88,078 |

| Other assets | | 4,927 | | | 5,220 |

| Total assets | $ | 423,219 | | $ | 383,527 |

| Liabilities and Stockholders’ Equity | | | |

| Current liabilities: | | | |

| Accounts payable | $ | 8,040 | | $ | 3,076 |

| Current operating lease liabilities | | 6,349 | | | 6,232 |

| Other accrued liabilities | | 47,366 | | | 33,155 |

| Accrued trade discounts and rebates | | 51,028 | | | 43,253 |

| Accrued returns reserve | | 17,674 | | | 18,969 |

| Other current liabilities | | 4,022 | | | 4,889 |

| Total current liabilities | | 134,479 | | | 109,574 |

| Long-term debt, net of unamortized debt issuance costs | | 189,713 | | | 220,335 |

| Non-current operating lease liabilities | | 30,004 | | | 31,531 |

| Other liabilities | | 20,239 | | | 8,398 |

| Total liabilities | | 374,435 | | | 369,838 |

| Total stockholders’ equity | | 48,784 | | | 13,689 |

| Total liabilities and stockholders’ equity | $ | 423,219 | | $ | 383,527 |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105731893/en/

Investor and Media Contact Cristi Barnett Vice President, Investor Relations [email protected]

Source: Xeris Biopharma Holdings, Inc.

Request email alerts

Search

PDF Version

Experienced biopharmaceutical executive brings global commercial leadership, financial expertise, and public company governance experience

CHICAGO--(BUSINESS WIRE)--Nov. 2, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced the appointment of Menassie M. Taddese to its Board of Directors, effective today. Taddese will also serve on the Board’s Audit Committee.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102898192/en/

Menassie M. Taddese

Menassie M. Taddese

“We are delighted to welcome Menassie to the Xeris Board,” said John Shannon, Chairman and Chief Executive Officer of Xeris. “His experience leading complex, pharmaceutical businesses, driving financial performance, and overseeing public company audit and governance matters will bring a valuable perspective to our Board. We look forward to benefiting from his leadership as we continue to execute our strategy and pursue long-term value creation.”

“I am pleased to join the Xeris Board of Directors as they continue to grow their commercial portfolio and advance their late-stage clinical pipeline medicine XP-8121,” said Mr. Taddese. “I look forward to working with my fellow Board members and the Xeris management team as they continue their disciplined execution.”

About Menassie M. Taddese

Menassie M. Taddese is a biopharmaceutical executive with nearly 30 years of global leadership experience spanning commercial operations, corporate finance, business transformation, and corporate governance. He most recently served as President, Emerging Markets at Viatris, where he led an approximately $3 billion business operating across more than 125 markets, spanning four major therapeutic areas, and employing approximately 3,500 people. During his tenure, he led the integration of the Mylan and Upjohn businesses, exceeded projected financial performance, and expanded operating margins.

Previously, Taddese spent more than 20 years at Pfizer in roles spanning corporate finance, treasury, commercial leadership, and general management. He was one of the founding leaders of Pfizer's Upjohn business and served as Vice President and Chief Financial Officer of Pfizer's Global Innovative Pharma Segment North America, an approximately $8 billion business.

In addition to his executive leadership experience, Taddese brings significant board and financial oversight expertise. He serves as an independent director and Chair of the Audit Committee at Medexus Pharmaceuticals (TSX: MDP). His other board and advisory roles include the Business Council for International Understanding, the American School of Dubai and One Acre Fund. He is also a Senior Advisor at EMIR Group.

Taddese holds an MBA in Finance with distinction from Penn State Smeal College of Business and completed an Executive Program in Management at Columbia Business School. His professional honors include the Pharmaceutical Executive Emerging Leader Award and the Penn State Smeal College of Business Distinguished Achievement Award.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines for serious diseases with significant unmet medical need. Xeris has three commercially available products: Recorlev®, a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for the treatment of hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for Xeris and its partners.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

Forward-Looking Statements

Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for Xeris Biopharma Holdings, Inc., including statements regarding, the composition of its Board of Directors, the Company’s ability to continue to demonstrate rapid growth of its commercial portfolio, the advancement of its pipeline, its ability to deliver long-term value for shareholders, future board capabilities, the market and therapeutic potential of its products and product candidates, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its collaborators’ ability to protect its intellectual property and proprietary technology, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs, and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261102898192/en/

Investor and Media Contact Cristi Barnett Vice President, Investor Relations [email protected]

Source: Xeris Biopharma Holdings, Inc.

Request email alerts

Search

PDF Version

Conference call and audio webcast to be held at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)--Oct. 22, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s third-quarter 2026 financial and operational results and business highlights.

Interested parties may pre-register for the call here or via the “Events” section of the Investor Relations website. It is recommended that attendees register 15 minutes prior to the scheduled webcast.

The webcast, replay and other information related to the event can be accessed on the investor website https://xerispharma.com/investor-relations.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines for serious diseases with significant unmet medical need. Xeris has three commercially available products: Recorlev®, a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for the treatment of hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for Xeris and its partners.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261022621233/en/

Investor and Media Contact Cristi Barnett Vice President, Investor Relations [email protected]

Source: Xeris Biopharma Holdings, Inc.

Request email alerts

Search

Prompts

Xeris Biopharma Holdings, Inc. (ticker XERS), listed in United States.

Company History

Date Change Detail
Jul 2, 2021 Renamed XERIS PHARMACEUTICALS INC → XERIS BIOPHARMA HOLDINGS, INC.

ETFs Holding Xeris Biopharma Holdings, Inc.

ETF Weight in ETF Shares Market value As of
JSML 0.75% 335,210 $ 2.708M Jul 31, 2026
JSMD 0.50% 644,770 $ 5.21M Jul 31, 2026
EHLS 0.34% 10,943 $ 182.748K Nov 17, 2026
FSEG 0.12% 836 $ 6,621.12 Jun 30, 2026
FESM 0.07% 546,918 $ 4.332M Jun 30, 2026
PSC 0.07% 211,875 $ 1.678M Jun 30, 2026
RESM 0.06% 284 $ 2,249.28 Jun 30, 2026
DFAS 0.04% 734,947 $ 12.237M Nov 12, 2026
MSSM 0.01% 10,486 $ 88.502K Aug 31, 2026
AVUQ 0.01% 3,175 $ 53.023K Nov 16, 2026
DFUS 0.01% 69,324 $ 1.154M Nov 12, 2026
DFAC 0.00% 168,346 $ 2.803M Nov 12, 2026
DCOR 0.00% 61,773 $ 1.029M Nov 12, 2026
DFAU 0.00% 7,484 $ 124.609K Nov 12, 2026
EBI 0.00% 14 $ 118.16 Aug 31, 2026